Organon & Co.

For the period ended Dec 31, 2025. Filed Feb 24, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 24, 2026

OGN$13.85-0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders Equity

Consolidated Statements of Stockholders’ Equity

($ in millions, except shares in thousands and per share amounts)

Common Stock · Additional Paid-In Capital · Retained Earnings · AccumulatedOtherComprehensive (Loss)Income · Total
Shares · Par Value
Balance at December 31, 2022	254,370	$3	$—	$(331)	$(564)	$(892)
Net income	—	—	—	1,023	—	1,023
Other comprehensive income, net of taxes	—	—	—	—	23	23
Cash dividends declared on common stock ($1.12 per share)	—	—	—	(295)	—	(295)
Stock-based compensation plans and other	1,256	—	25	59	—	84
Net transfers to Merck & Co., Inc., including Separation Adjustments	—	—	—	(13)	—	(13)
Balance at December 31, 2023	255,626	$3	$25	$443	$(541)	$(70)
Net income	—	—	—	864	—	864
Other comprehensive loss, net of taxes	—	—	—	—	(108)	(108)
Cash dividends declared on common stock ($1.12 per share)	—	—	—	(297)	—	(297)
Stock-based compensation plans and other	2,173	—	83	—	—	83
Balance at December 31, 2024	257,799	$3	$108	$1,010	$(649)	$472
Net income	—	—	—	187	—	187
Other comprehensive income, net of taxes	—	—	—	—	122	122
Cash dividends declared on common stock ($0.34 per share)	—	—	—	(88)	—	(88)
Stock-based compensation plans and other	2,517	—	59	—	—	59
Balance at December 31, 2025	260,316	$3	$167	$1,109	$(527)	$752

-65-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.